

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 321/28, 323/42, C07D 213/62, 213/70, 213/78, 277/06, 327/06, 339/02, 339/08, 401/12, 471/04, 487/04	A1	(11) International Publication Number: WO 98/42661
		(43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/IL98/00144 (22) International Filing Date: 26 March 1998 (26.03.98) (30) Priority Data: 120531 26 March 1997 (26.03.97) IL (71) Applicant (for all designated States except US): YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HE- BREW UNIVERSITY OF JERUSALEM [IL/IL]; Jabotin- sky Street 146, 92182 Jerusalem (IL). (72) Inventor; and (75) Inventor/Applicant (for US only): HAJ-YEHIA, Abdullah [IL/IL]; The Hebrew University of Jerusalem, Faculty of Medicine/School of Pharmacy, The Adolph Weinberger Building, P.O. Box 12065, 91120 Jerusalem (IL). (74) Agent: EITAN, PEARL, LATZER & COHEN-ZEDEK; Lumir House, Maskit Street 22, 46733 Herzelia (IL).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: AROMATIC AND HETEROCYCLIC NITRATO DERIVATIVES		
(57) Abstract An organic compound is provided which contains at least one nitric oxide donor group and at least one group being, or being adapted to be converted in vivo to a free sulfhydryl group. A preferred compound contains at least one sulfhydryl group, either in the reduced -SH form or in the oxidized -S-S-disulfide form.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AROMATIC AND HETEROCYCLIC NITRATO DERIVATIVES

FIELD OF THE INVENTION

There are provided novel organic compounds and pharmaceutical compositions comprising same. The compounds are *in vivo* nitric oxide donors and they contain at least one sulfhydryl group, either in the reduced -SH form or in the oxidized -S-S disulfide form.

Preferably the compounds containing the -S-S groups are five- or six membered heterocyclic compounds, where such a group is part of the heterocyclic nucleus, to which there may be attached directly or via a hydrocarbyl chain, which may be optionally substituted, one or more -ONO₂ groups.

The -S-S group may be a bridging member between to cyclic or two heterocyclic moieties each of which bears at least one -ONO₂ group.

Another suitable group of compounds comprises a 5- or 6-membered aromatic ring substituted with an -SH group and a -ONO₂ bearing group and there are also provided compounds having a 5-membered ring system containing a nitrogen and a non-adjacent S atom, substituted by at least one group bearing an -ONO₂ substituent and which may have also an -SH group as substituent.

All the above compounds are such that they will undergo *in vivo* metabolic cleavage to provide free -SH groups.

The novel compounds are effective substitutes for existing tolerance inducing organic or inorganic nitric oxide donors.

BACKGROUND OF THE INVENTION:

For over a century, the nitric oxide (NO) donor nitroglycerin (GTN) has been the mainstay in the treatment of angina and related heart diseases. However, the existing mechanisms proposing the mediation of GTN action by free NO, intracellular or extracellular S-nitrosothiol formation and subsequent activation of guanylyl cyclase (GC), as well as those describing GTN tolerance, have become increasingly controversial. The phenomenon of tolerance to GTN, however, is of special clinical importance. In fact, early tolerance to the anti-anginal effects of the drug is the major drawback of nitrate therapy, especially during acute myocardial infarction. This is particularly important since alternative non-tolerance inducing agents have not yet been developed to successfully replace therapy with GTN.

Based on accumulating evidence from our laboratory, we hypothesize that GTN may directly interact with SH-group/s located on its target enzyme (GC) resulting in its S-nitrosylation and activation. However, subsequent auto-oxidation (disulfide-formation) of these SH-groups render the enzyme inert towards further reaction with GTN, resulting in tolerance development.

Additionally, evidence has recently been provided to support an involvement of the superoxide anion in the mechanism/s

underlying GTN tolerance and cross-tolerance. According to these reports, increased production of superoxide anion was found to accompany tolerance development to GTN in vascular tissue. Treatment with superoxide dismutase (SOD), significantly enhanced relaxation of control and tolerant vascular tissue to GTN and other exogenous and endogenous vasodilators.

While the precise mechanism for the vasorelaxant effect of GTN is unknown, a consensus exists regarding the primary involvement of cGMP in mediating the nitrate-induced relaxation. However, the roles of sulfhydryl groups [reduced glutathione (GSH) and cysteine (Cys)] and of various enzymes in the bioconversion of GTN and subsequent activation of guanylyl cyclase (GC) leading to relaxation have become increasingly controversial. Cysteine was found to be the specific sulfhydryl required for activation of soluble coronary arterial GC and to be the only one of several sulfhydryls to react non-enzymatically with GTN at physiologic pH resulting in formation of S-nitrosocysteine [1,2]. Since S-nitrosothiols were shown to be potent activators of GC [3,4], S-nitrosocysteine/thiol were proposed as the intracellular mediators of organic nitrate-induced vasorelaxation [5]. Additionally, N-acetylcysteine (NAC, an immediate donor of Cys thereby increasing GSH) was reported to potentiate GTN activity in vitro and in vivo [6-10]. The enhanced reaction of thiols with GTN in plasma and blood versus buffer suggested that activation of GC by GTN may be

mediated via extracellular formation of S-nitrosothiol/s [7]. In either case (intra or extracellular S-nitrosothiol formation), this association between sulfhydryls and GTN activity has long been recognized as evidence for the "thiol depletion hypothesis". However, recent studies from our laboratory [11] and those of Boesgard et al., [9] revealed a dissociation between tissue thiol content (measured as Cys and GSH) and nitrate tolerance in vivo.

In vitro inhibitory studies provide indirect support for the involvement of enzymes in GTN bioactivation [glutathione S-transferase (GST) and cytochrome P-450 (P-450)]. However, in view of several other reports suggesting the lack of any significant role of GST and P-450, in GTN bioactivation, the reduced bioactivation of GTN is unlikely to be the main factor underlying nitrate tolerance in vivo. In fact, reduced cGMP production was also shown to follow exposure of vascular preparation to direct NO-donors, for which no definitive metabolic pathway has been reported.

Furthermore, recent work from our laboratory presented in vivo evidence excluding the involvement of any particular metabolic pathway since reduced cGMP was also shown to follow treatment with S-alkylating agents in the absence of GTN

Each sulfhydryl may be present in a free form (SH), separately protected form (acetyl, carbamyl or other), or as an atom in a heterocyclic compound. In cases where the a compound contains two sulfhydryl groups, these can exist in the reduced (SH) or the oxidized (disulfide) form. However, each one of the compounds can also be regarded as a parent pro-drug which is assumed to undergo metabolic reduction or cleavage to provide the free SH groups in vivo.

Heart disease is the leading cause of death in Western society and is rapidly approaching this leading position worldwide. Ischemic heart disease (IHD) is the most common heart disease. For over a century, nitroglycerin and other organic nitrates have been used for the treatment of various types of myocardial ischemia, including acute myocardial infarction (AMI), and as adjuncts in the treatment of other heart diseases (congestive heart failure and resistant hypertension). Chronic prophylaxis and acute treatment are necessary to prevent complications of IHD with potential fatal outcomes (~25% death for AMI). Tolerance to the anti-ischemic effect of these drugs is, by far, the most serious drawback of therapy with currently available organic nitrates. The compounds proposed in this application constitute a novel approach to overcome tolerance.

Because of their SH-content (radical scavenging and anti-oxidant properties), these compounds may also be applied for other pathologies.

Thus, considering their promising chemical and pharmacological characteristics and the ever increasing demand for better therapy for heart diseases significant potential exists for compounds of this type to become, the next generation of vasodilators. This is especially true concerning the considerable amount of recent evidence indicating the involvement of nitric oxide, reactive oxygen species and thiols in a variety of conditions, the pathogenesis of which as well as the treatment for, have not been fully resolved. These include (but not limited to): atherosclerosis, pulmonary and systemic hypertension, asthma and other related respiratory diseases, trauma, shock, neurotoxicity, neurodegenerative and

neurologic disorders, including those involving learning, memory, olfaction and nociception, Huntington, Alzheimer and Parkinson's diseases, multiple sclerosis and convulsive (seizure) disorders, AIDS-related disorders (i.e., dementia), disorders of gastric acid and other secretory and peristaltic functions of the alimentary system, drug and disease-induced neuropathy and nephropathy, pathological and premature uterine contractions, cellular defense impairment, and insulin-resistance in glucose intolerance and diabetes mellitus, pregnancy-induced hypertension, chemotaxis and phagocytic impairment in immunological disorders, cerebrovascular diseases, aggregation disorders, penile erection and treatment of male impotence [x-y].

Although the exact mechanisms defining organic nitrates and other nitric oxide-donors action and tolerance are not completely elucidated, the primary roles of nitric oxide (being their first messenger) and cGMP (the second messenger) in mediating vasorelaxation is universally accepted. Our preliminary results utilizing example compounds 1 to 6 from Figure 1 show that, unlike currently available organic and inorganic nitrates, these compounds possess equipotent or even superior vasorelaxant activity. Moreover, using cGMP measurements both in vitro and in vivo show that these compounds do not produce tolerance even after extended periods of exposure to the drug when used, for example, in nitroglycerin-equimolar dosing regimens for which tolerance to the cGMP-inducing activity of nitroglycerin has been documented under the same experimental conditions (Table 1).


According to this invention, whenever a compound exists in the acid form, the term 'acid' should also be understood to include the corresponding acid halide, salts with pharmacologically acceptable alkali metal (including alkaline earth metal and ammonium bases), ester and amides. Moreover, the alcohol or the amines used to form the corresponding ester and amides of the acid can also bear a nitrate ester.

The present invention is concerned with pharmaceutical compositions, with new pharmaceutically-active compounds, the methods of their use and with the preparation thereof.


The invention relates to nitric oxide donors, being an organic compound containing at least one nitric oxide donor group, and at least one group being, or being adapted to be converted *in vivo* to a free sulfhydryl group. Preferred are compounds which contains at least one sulfhydryl group, either in the reduced -SH form or in the oxidized -S-S-disulfide form.

Preferred are such compounds which contain a 5- or 6-membered ring which, contains 2 conjugate -S- atoms, substituted by one or more -ONO₂ groups or linked to one or more substituents bearing a terminal -ONO₂ group, or where the -S-S-group is in an open configuration, linked to at least one aromatic nucleus or a heterocyclic nucleus with a nitrogen in the ring structure, which rings bear a substituent with a terminal -ONO₂ group or where the compound is a five-membered hetrocycle containing a -S- atom and a nitrogen substituted with at least one substituent with a terminal -ONO₂ group.


Specific new compounds are:




1




2




3




4




5




6




7




8




9




10




11




12



13




14




15


Another type of novel compound is




1



2




3




4











5









6




7









21




22




23




24




25




26




27




28




29



30



31




32


The invention also relates to pharmaceutical composition for the treatment of disorders where nitric oxide donors are indicated, which comprises as active ingredient an organic compound containing at least one nitric oxide donor group, and at least one group being, or being converted *in vivo* to a free sulfhydryl group, as defined above. Such a compound can be one which contains at least one sulfhydryl group, either in the reduced -SH form or in the oxidized -S-S disulfide form.

Preferred are compositions where the active compound contains a 5- or 6-membered ring compound containing 2 conjugate -S- atoms, substituted by one or more -ONO₂ groups or linked to one or more substituents bearing a terminal -ONO₂ group, or where the -S-S group is in an open configuration, linked to at least one aromatic nucleus or a heterocyclic nucleus with a nitrogen in the ring structure, which rings bear a substituent with a terminal -ONO₂ group or where the compound is a five-membered heterocycle containing a -S- atom and a nitrogen substituted with at least one substituent with a terminal -ONO₂ group.


Preferred compositions contain as active ingredient a compound such as:




1




2




3




4




8




9




10




11




12



13




14




15








5




6




7







21




22




23




24




25




26






27




28




29




Other pharmaceutical compositions are those where the active compound is selected from:




1




2




3




4




5




6




7




8




9




10




11




12



13



14



15

For the preparation of pharmaceutical compositions, the novel compounds are mixed in the usual way with appropriate pharmaceutical carrier substances, aroma, flavoring and coloring materials and formed, for example, into tablets or dragees of immediate or sustained release or, with additions of appropriate adjuvants, for example, water or an oil, such as olive or other oil, are suspended or dispersed or dissolved.

The compounds or the pharmaceutical composition thereof can be administered orally (including the sublingual and buccal routes) or via an injectable form (including the subcutaneous, intramuscular, intraperitoneal and the parenteral routes). Other routes of administration such as aerosols and dermal preparations are also to be considered. As injection medium, water is preferably used which contains the stabilizing agents, solubilizing agents and/or buffers usually utilized in the preparations of solutions for injections. Such additives include, for example, tartarate and borate buffers, ethanol, ethylene and propylene glycols, glycerol, dimethyl sulphoxide, complex formers (i.e., ethylenediamine tetraacetic acid), high molecular weight polymers (such as liquid polyethylene oxide) for viscosity regulation and polyethylene derivatives of sorbit anhydrides. Solid carrier materials include, for example, starch, lactose, mannitol, methyl cellulose, talc, highly dispersed silicic acid, high molecular weight polymers (i.e., polyethylene glycol). Compositions suitable for oral administration (as defined above) can, if necessary, contain flavoring and sweetening agents.

It will be understood that the compounds shown demonstrate the principal upon which this invention is based. Thus, the specification and examples given in this application are illustrative but not limitative of the present invention and that embodiments within the spirit and scope of the invention will suggest themselves to those skilled in the art.

The synthesis of the novel compounds carried out utilizing conventional organic synthetic methods. The following examples are given for the purpose of illustrating the present invention:

Example 1:

trans-1,2-Dinitrato-4,5-dithiane (compound 1, Figure 1)

This compound was easily synthesized utilizing the commercially available precursor *trans*-1,2-dihydroxy-4,5-dithiane. 0.5g of the precursor was added portionwise to chilled (-5° C) 1:1 mixture of fuming nitric sulfuric acids. Upon completion of the addition, the ice/salt bath was removed and the mixture brought to room temperature. This mixture was added dropwise to a cooled mixture of dry diethyl ether:acetonitrile:water (70:20:10) with vigorous stirring. The lower aqueous phase was separated and extracted twice with diethyl ether. The combined organic extracts were washed twice with water and once with cold 1% sodium carbonate solution. The organic layer was dried over magnesium sulfate, and evaporated to near dryness under reduced pressure. The residual oil was loaded on a silica column and separated after elution with hexane. Evaporation under reduced pressure of the eluate yielded a yellowish oil (0.56g) with analytical data consistent with the structure of *trans*-1,2-dinitrato-4,5-dithiane.

Example 2:

2,2'-Dithiodiethanol-dinitrate (compound 2, Figure 1)

This compound was synthesized in a similar fashion as compound 1 above using the commercially available precursor 2,2'-dithiodiethanol as the starting material. The precursor was nitrated and separated as above yielding the title compound 2,2'-dithiodiethanol-dinitrate.

Example 3:

1,1-Diemethanol-dinitrate-3,4-dithiane (compound 3, Figure 1)

This compound was synthesized by bishydroxymethylation of diethyl malonate followed by thiolation of the hydroxyl groups (via the halide intermediate). The resulting 1,1-dicarboxy-3,4-dithiane was reduced by borane (catechol borane solution) to the corresponding 1,1-diemethanol-3,4-dithiane. Direct nitration of this latter intermediate yielded the title compound 1,1-diemethanol-dinitrate-3,4-dithiane.

Example 4:

1,1'-Bisthiomethyl-3,4-dihydroxy-cyclohexane-dinitrate ester

This compound was synthesized by thiolation of the dichloride intermediate of the commercially available 1,1'-bishydroxymethyl-3-cyclohexene. Oxidation of the double bond either by hydrogen peroxide/osmium tetroxide to generate the *cis*-diol or by a peracid/formic acid mixture to generate the *trans*-diol followed by nitration of the diol will generate the corresponding (*cis* or *trans*) form of the title compound.

Example 5:

Thioctyl alcohol nitrate ester (compound 5, Figure 1)

This compound was synthesized in a high yield process utilizing thioctic acid as the precursor. Following reduction of the acid (or its methyl or ethyl ester) by catechol borane solution, the resulting thioctyl alcohol was separated and nitrated as described above to yield the title compound.

Example 6:

1,2-Dihydroxy-dinitrate-6,8-dithiane (compound 6, Figure 1)

2-Hydroxy lipoic (thioctic) acid was synthesized from thioctic acid via the 2-bromo derivative. This intermediate was reduced via borane to yield the direct precursor.

1,2-dihydroxy-6,8-dithiane which, upon nitration as described above, yielded the title compound.

Experimental Report

Representative for the new compounds, the vasorelaxant activities (measured as the ability of the tested drug to induce an increase in vascular cGMP) of the example compounds 1 to 6 were determined and compared to activity of nitroglycerin under the same experimental conditions following single and sustained exposure of rats to the compound.

For this purpose the compound to be tested was administered, in each case, to 8 male Sprague-Dawley rats (300-400g) before and after an 18 hr continuous intravenous infusion of the compound. The 18 hr continuous infusion period was determined based on existing data demonstrating the development of tolerance to the drug effect in the case of nitroglycerin. The existence of tolerance to the drug is demonstrated by the inability of the drug to attain 50% or more of the cGMP values measured in the vascular tissue after dosing of the drug to previously treated animals as compared to controls (non-treated or vehicle-treated animals). After drug administration (i.v. push), the rat was sacrificed, the aorta immediately removed and processed for cGMP measurement as has been described in detail by us (z). All of the tested new compounds were utilized in nitroglycerin-equimolar doses, either before or after the 'tolerance' induction period.

The following table summarizes the results obtained following administration of either nitroglycerin or the tested compounds before and after an 18 hr continuous exposure to the same compound:

<u>Tested Compound</u>	<u>cGMP (pmol/g tissue)</u>	
	<u>Pre-infusion</u>	<u>Post-infusion</u>
Nitroglycerin	153 ± 13	68 ± 9**
Compound 1	196 ± 14	189 ± 13*
Compound 2	169 ± 12	174 ± 13*
Compound 3	171 ± 14	174 ± 16*
Compound 4	149 ± 11	169 ± 13*
Compound 5	123 ± 13	113 ± 11*
Compound 6	193 ± 17	179 ± 12*


**Significantly different from the pre-infusion values and denotes tolerance.

*Not significantly different from pre-infusion levels and denotes the lack of tolerance.


Besides their expected superior vasorelaxant activity, these results clearly demonstrate that whereas tolerance to the cGMP-inducing activity of nitroglycerin developed early (18 hr) following its continuous in vivo administration, no tolerance was observed to the cGMP-increasing effects of the novel compounds under the same experimental conditions used for the induction of in vivo tolerance. In fact, preliminary results from ongoing experiments in our laboratory show that no tolerance to this cGMP-inducing effect of these novel SH-containing-NO-donors develop even after exposure of the animals to the compounds for extended periods of time (i.e., not even after 168 hr of continuous intravenous infusions).

CLAIMS


1. A nitric oxide donors being an organic compound containing at least one nitric oxide donor group, and at least one group being, or being adapted to be converted *in vivo* to a free sulfhydryl group.
2. A compound according to claim 1, which contains at least one sulfhydryl group, either in the reduced -SH form or in the oxidized -S-S disulfide form.
3. A compound according to claim 1 or 2, which contains a 5- or 6-membered ring compound containing 2 conjugate -S- atoms, substituted by one or more -ONO₂ groups or linked to one or more substituents bearing a terminal -ONO₂ group, or where the -S-S group is in an open configuration, linked to at least one aromatic nucleus or a heterocyclic nucleus with a nitrogen in the ring structure, which rings bear a substituent with a terminal -ONO₂ group or where the compound is a five-membered hetrocycle containing a -S- atom and a nitrogen substituted with at least one substituent with a terminal -ONO₂ group.
4. A compound according to claim 1 selected from:




1




2




3




4




5




6




7




8




9




10




11




12



13











14









15

5. A compound according to claim 1, selected from












21




22




23




24




25




26






27




28



29




6. A pharmaceutical composition for the treatment of disorders where a nitric oxide donors are indicated, which comprises as active ingredient an organic compound containing at least one nitric oxide donor group, and at least one group being, or being converted *in vivo* to a free sulfhydryl group.
7. A composition according to claim 6, where the active compound is one which contains at least one sulfhydryl group, either in the reduced -SH form or in the oxidized -S-S disulfide form.
8. A composition according to claim 6 or 7, where the active compound contains a 5- or 6-membered ring compound containing 2 conjugate -S- atoms, substituted by one or more -ONO₂ groups or linked to one or more substituents bearing a terminal -ONO₂ group, or where the -S-S group is in an open configuration, linked to at least one aromatic nucleus or a heterocyclic nucleus with a nitrogen in the ring structure, which rings bear a substituent with a terminal -ONO₂ group or where the compound is a five-membered hetrocycle containing a -S- atom and a nitrogen substituted with at least one substituent with a terminal -ONO₂ group.
9. A pharmaceutical composition according to claim 6 where the active ingredient is selected from:




1



2




3




4




5




6




7




8




9




10




11




12








13




14




15







21




22




23




24




25




26






27




28




29




10. A pharmaceutical composition according to Claim 6, where the active compound is selected from:




1




2




3




4




5




6




7




8




9




10




11




12



13



14



15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/L98/00144

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 546/114, 261, 296, 297, 298; 548/188; 549/15, 21, 32, 35, 49; 562/430; 564/162; 568/22

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE Structure Searching In File Registry, File CAPlus, File Beilstein and File Marpat.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, Vol.125, No.6, 14 October 1996 (Columbus, OH, USA), page 649, column 1, the abstract No. 125:204,523g, SHIRAISHI et al. "Drugs For Improvement of Lipid Metabolism," Jpn. Kokai Tokyo Koho JP 08,175,994[96,175,994]	1-10

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 AUGUST 1998

Date of mailing of the international search report

01 SEP 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ALAN L. ROTMAN

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IL98/00144

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-3 and 6-8
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Claims 1-3 and 6-8 were found unsearchable to the extent that no structure was provided, only substituent groupings or portions of structures.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL98/00144

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07C 321/28, 323/42; C07D 213/62, 213/70, 213/78, 277/06, 327/06, 339/02, 339/08, 401/12, 471/04, 487/04

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

546/114, 261, 296, 297, 298; 548/188; 549/15, 21, 32, 35, 49; 562/ 430; 564/162; 568/22

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

GROUP I: Claims (1-3, 6-8) in so far as they read on the inventions of claims 4, 5, 9 and 10 in-part drawn to structures 1-3, 5 and 15 wherein the term [X] in the depicted formulas represents O-NO₂ or SH and the term [Y] represents SH or O-Ac. The mercapto-benzoic acid derivatives assigned to this Group are classified in Class 562; Subclass 430.

GROUP II: Claims (1-3, 6-8) in so far as they read on the inventions of claims 4, 5, 9 and 10 in-part drawn to structure four. The involved structure is drawn to a 2-mercapto-3-pyridine-carboxylic acid derivative.

GROUP III: Claims (1-3, 6-8) in so far as they read on the inventions of claims 4, 5, 9 and 10 in-part drawn to structures 6-9 and 12. The depicted Group III structures represent 2-mercaptopyridine 3-carboxamido-N-lower-alkylene nitrate and 2-mercapto-pyridine lower-alkylene nitrate and derivatives.

GROUP IV: Claims (1-3, 6-8) in so far as they read on the inventions of claims 4, 5, 9 and 10 in-part drawn to structures 10, 11, 13 and 14. The depicted Group IV structures represent 2-oxazolidine-4-carboxylic acid derivatives.

GROUP V: Claims (1-3, 6-8) in so far as they read on the inventions of claims 5 and 10 in-part drawn to structure 1, which represents 1,2-dithiane-4,5-dinitrate compound.

GROUP VI: Claims (1-3, 6-8) in so far as they read on the inventions of claims 5 and 10 in-part drawn to structure 1, which represents an acyclic disulfide-dinitrate.

GROUP VII: Claims (1-3, 6-8) in so far as they read on the inventions of claims 5 and 10 in-part drawn to structures 3, 5-10 and 15-17, which represents 1,2-dithiolane di- or trinitrate derivatives.

GROUP VIII: Claims (1-3, 6-8) in so far as they read on the inventions of claims 5 and 10 in-part drawn to structures 4, 12 and 13, which represent spiro-1,2-dithiolane derivatives.

GROUP IX: Claims (1-3, 6-8) in so far as they read on the inventions of claims 5 and 10 in-part drawn to structures 14 and 19, which represent hexahydro-benzo-1,2-dithiols.

GROUP X: Claims (1-3, 6-8) in so far as they read on the inventions of claims 5 and 10 in-part drawn to structures 18 and 21, which represent benzo-1,2-dithiin derivatives.

GROUP XI: Claims (1-3, 6-8) in so far as they read on the inventions of claims 5 and 10 in-part drawn to structures 20 and 22, which represent pyrido-1,2-dithiin derivatives.

GROUP XII: Claims (1-3, 6-8) in so far as they read on the inventions of claims 5 and 10 in-part drawn to structures 23, and 26-28, which represent bis-(4-pyridyl-sulfide) derivatives.

GROUP XIII: Claims (1-3, 6-8) in so far as they read on the inventions of claims 5 and 10 in-part drawn to structures 24, 25 and 29, which represent bis-(2-phenylcarboxamido-N-ethylene-nitrate) derivatives.

The inventions listed as Groups I-XIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: There is no single common core or nucleus and each core does not possess the same pharmacological properties.